Fierce Pharma1d
Zevra Therapeutics embarks on diagnosis push as Miplyffa launch gains steam
It’s been just six months since Zevra Therapeutics scored an FD | Niemann-Pick disease type C therapy Miplyffa became ...
Zevra Therapeutics price target raised to $22 from $20 at Guggenheim
Guggenheim raised the firm’s price target on Zevra Therapeutics (ZVRA) to $22 from $20 and keeps a Buy rating on the shares. The Miplyffa ...
Zevra Therapeutics price target raised to $25 from $23 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Zevra Therapeutics (ZVRA) to $25 from $23 and keeps a Buy rating on the ...